IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.050
0.00 (0.00%)
Sep 4, 2025, 3:37 PM - Market open
IceCure Medical Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for IceCure Medical stock has a target of 2.00, which predicts a 90.48% increase from the current stock price of 1.05.
Price Target: $2.00 (+90.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for IceCure Medical is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2.5 → $2 | Strong Buy | Maintains | $2.5 → $2 | +90.48% | Aug 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +138.10% | May 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +138.10% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +138.10% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +138.10% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
5.34M
from 3.29M
Increased by 62.11%
Revenue Next Year
12.96M
from 5.34M
Increased by 142.91%
EPS This Year
-0.21
from -0.30
EPS Next Year
-0.18
from -0.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | 29.0M | |||
| Avg | 5.3M | 13.0M | |||
| Low | 2.4M | 5.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 217.9% | 443.9% | |||
| Avg | 62.1% | 142.9% | |||
| Low | -27.0% | -6.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.18 | -0.06 | |||
| Avg | -0.21 | -0.18 | |||
| Low | -0.23 | -0.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.